Shares of Becton, Dickinson and Company (NYSE:BDX – Get Rating) have been assigned an average recommendation of “Moderate Buy” from the twelve research firms that are presently covering the stock, Marketbeat reports. One analyst has rated the stock with a hold recommendation and eight have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued ratings on the stock in the last year is $276.60.
A number of equities analysts have issued reports on BDX shares. Piper Sandler upgraded Becton, Dickinson and from a “neutral” rating to an “overweight” rating and increased their price objective for the stock from $260.00 to $290.00 in a report on Friday, May 5th. StockNews.com started coverage on Becton, Dickinson and in a report on Thursday, May 18th. They issued a “buy” rating for the company. Barclays increased their price objective on Becton, Dickinson and from $282.00 to $284.00 in a report on Monday, May 8th. Evercore ISI decreased their price objective on Becton, Dickinson and from $280.00 to $275.00 and set an “outperform” rating for the company in a report on Tuesday, April 4th. Finally, Morgan Stanley increased their target price on Becton, Dickinson and from $290.00 to $295.00 and gave the stock an “overweight” rating in a research note on Friday, February 3rd.
Institutional Inflows and Outflows
A number of institutional investors have recently bought and sold shares of the company. Fairfield Bush & CO. bought a new position in shares of Becton, Dickinson and in the first quarter worth about $114,000. Sequoia Financial Advisors LLC raised its stake in shares of Becton, Dickinson and by 11.3% in the first quarter. Sequoia Financial Advisors LLC now owns 2,923 shares of the medical instruments supplier’s stock worth $778,000 after buying an additional 297 shares during the period. Brighton Jones LLC raised its stake in shares of Becton, Dickinson and by 8.8% in the first quarter. Brighton Jones LLC now owns 1,383 shares of the medical instruments supplier’s stock worth $368,000 after buying an additional 112 shares during the period. Zions Bancorporation N.A. raised its stake in shares of Becton, Dickinson and by 13.0% in the first quarter. Zions Bancorporation N.A. now owns 504 shares of the medical instruments supplier’s stock worth $134,000 after buying an additional 58 shares during the period. Finally, Mather Group LLC. raised its stake in shares of Becton, Dickinson and by 26.0% in the first quarter. Mather Group LLC. now owns 1,346 shares of the medical instruments supplier’s stock worth $358,000 after buying an additional 278 shares during the period. Institutional investors own 87.08% of the company’s stock.
Becton, Dickinson and Price Performance
Becton, Dickinson and (NYSE:BDX – Get Rating) last announced its earnings results on Thursday, May 4th. The medical instruments supplier reported $2.86 EPS for the quarter, beating analysts’ consensus estimates of $2.75 by $0.11. The company had revenue of $4.82 billion during the quarter, compared to the consensus estimate of $4.67 billion. Becton, Dickinson and had a return on equity of 12.98% and a net margin of 8.59%. The firm’s revenue for the quarter was up 1.5% on a year-over-year basis. During the same quarter in the prior year, the company earned $3.18 earnings per share. As a group, equities research analysts forecast that Becton, Dickinson and will post 12.19 earnings per share for the current year.
Becton, Dickinson and Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, June 30th. Shareholders of record on Friday, June 9th will be issued a $0.91 dividend. This represents a $3.64 dividend on an annualized basis and a yield of 1.51%. The ex-dividend date of this dividend is Thursday, June 8th. Becton, Dickinson and’s dividend payout ratio is 68.29%.
About Becton, Dickinson and
Becton, Dickinson & Co engages in the development, manufacture, and sale of medical supplies, devices, laboratory equipment, and diagnostic products. It operates through the following segments: BD Medical, BD Life Sciences, and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery.
- Get a free copy of the StockNews.com research report on Becton, Dickinson and (BDX)
- Ralph Lauren’s Styled Dividend Is Still In Season
- Dollar Tree Falls As Theft Cuts Into Bottom Line
- Best Buy’s Comeback Is Still At Play, Earnings Call For Patience
- e.l.f. Beauty Has Giant Quarter, Shares Hit New High
- If You Can Only Pick One Stock For The Rest Of 2023, Pick Nvidia
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.